BioTelemetry (BEAT) Sets New 12-Month High at $47.65

BioTelemetry Inc (NASDAQ:BEAT) shares hit a new 52-week high during trading on Thursday . The company traded as high as $47.65 and last traded at $47.35, with a volume of 8568 shares trading hands. The stock had previously closed at $46.55.

A number of research analysts recently commented on the stock. TheStreet raised shares of BioTelemetry from a “c” rating to a “b-” rating in a research report on Tuesday, May 29th. BidaskClub raised shares of BioTelemetry from a “hold” rating to a “buy” rating in a research report on Friday, March 9th. ValuEngine raised shares of BioTelemetry from a “hold” rating to a “buy” rating in a research report on Friday, April 27th. Benchmark reissued a “buy” rating and issued a $46.00 target price (up from $44.00) on shares of BioTelemetry in a research report on Thursday, April 26th. Finally, Zacks Investment Research downgraded shares of BioTelemetry from a “hold” rating to a “sell” rating in a research report on Wednesday, April 25th. One investment analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $46.14.

The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.83 and a current ratio of 1.96. The stock has a market capitalization of $1.52 billion, a P/E ratio of 48.81, a P/E/G ratio of 3.49 and a beta of 1.41.

BioTelemetry (NASDAQ:BEAT) last posted its earnings results on Wednesday, April 25th. The medical research company reported $0.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.16. The company had revenue of $94.50 million during the quarter, compared to the consensus estimate of $91.55 million. BioTelemetry had a negative net margin of 3.13% and a positive return on equity of 16.63%. The company’s revenue for the quarter was up 69.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.16 earnings per share. equities analysts anticipate that BioTelemetry Inc will post 1.33 EPS for the current fiscal year.

In related news, CFO Heather C. Getz sold 65,570 shares of the company’s stock in a transaction on Thursday, April 26th. The shares were sold at an average price of $38.03, for a total transaction of $2,493,627.10. Following the completion of the sale, the chief financial officer now directly owns 84,156 shares of the company’s stock, valued at approximately $3,200,452.68. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kirk E. Gorman sold 7,500 shares of the company’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $45.49, for a total transaction of $341,175.00. Following the sale, the director now directly owns 180,815 shares of the company’s stock, valued at $8,225,274.35. The disclosure for this sale can be found here. Insiders sold 486,104 shares of company stock valued at $20,406,992 over the last three months. Insiders own 9.60% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. American International Group Inc. boosted its holdings in shares of BioTelemetry by 11.4% during the 4th quarter. American International Group Inc. now owns 25,139 shares of the medical research company’s stock worth $752,000 after buying an additional 2,568 shares during the period. Macquarie Group Ltd. boosted its holdings in shares of BioTelemetry by 8,866.8% during the 4th quarter. Macquarie Group Ltd. now owns 756,263 shares of the medical research company’s stock worth $22,612,000 after buying an additional 747,829 shares during the period. Arizona State Retirement System boosted its holdings in shares of BioTelemetry by 223.7% during the 4th quarter. Arizona State Retirement System now owns 51,670 shares of the medical research company’s stock worth $1,545,000 after buying an additional 35,710 shares during the period. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of BioTelemetry by 180.6% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 29,434 shares of the medical research company’s stock worth $880,000 after buying an additional 18,945 shares during the period. Finally, Lyon Street Capital LLC boosted its holdings in shares of BioTelemetry by 2,368.9% during the 4th quarter. Lyon Street Capital LLC now owns 379,029 shares of the medical research company’s stock worth $11,333,000 after buying an additional 363,677 shares during the period. 93.40% of the stock is owned by institutional investors and hedge funds.

BioTelemetry Company Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply